These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37812725)

  • 1. Adaptor protein-3 produces synaptic vesicles that release phasic dopamine.
    Jain S; Yee AG; Maas J; Gierok S; Xu H; Stansil J; Eriksen J; Nelson AB; Silm K; Ford CP; Edwards RH
    Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2309843120. PubMed ID: 37812725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine.
    Jain S; Yee AG; Maas J; Gierok S; Xu H; Stansil J; Eriksen J; Nelson A; Silm K; Ford CP; Edwards RH
    bioRxiv; 2023 Aug; ():. PubMed ID: 37609166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.
    Onoa B; Li H; Gagnon-Bartsch JA; Elias LA; Edwards RH
    J Neurosci; 2010 Jun; 30(23):7917-27. PubMed ID: 20534840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice.
    Croft BG; Fortin GD; Corera AT; Edwards RH; Beaudet A; Trudeau LE; Fon EA
    Mol Biol Cell; 2005 Jan; 16(1):306-15. PubMed ID: 15496457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The redistribution of Drosophila vesicular monoamine transporter mutants from synaptic vesicles to large dense-core vesicles impairs amine-dependent behaviors.
    Grygoruk A; Chen A; Martin CA; Lawal HO; Fei H; Gutierrez G; Biedermann T; Najibi R; Hadi R; Chouhan AK; Murphy NP; Schweizer FE; Macleod GT; Maidment NT; Krantz DE
    J Neurosci; 2014 May; 34(20):6924-37. PubMed ID: 24828646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size.
    Pothos EN; Larsen KE; Krantz DE; Liu Y; Haycock JW; Setlik W; Gershon MD; Edwards RH; Sulzer D
    J Neurosci; 2000 Oct; 20(19):7297-306. PubMed ID: 11007887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptor protein AP-3 produces synaptic vesicles that release at high frequency by recruiting phospholipid flippase ATP8A1.
    Xu H; Oses-Prieto JA; Khvotchev M; Jain S; Liang J; Burlingame A; Edwards RH
    Nat Neurosci; 2023 Oct; 26(10):1685-1700. PubMed ID: 37723322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters.
    Mulvihill KG
    Neurochem Int; 2019 Jan; 122():94-105. PubMed ID: 30465801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic Vesicle Recycling Pathway Determines Neurotransmitter Content and Release Properties.
    Silm K; Yang J; Marcott PF; Asensio CS; Eriksen J; Guthrie DA; Newman AH; Ford CP; Edwards RH
    Neuron; 2019 May; 102(4):786-800.e5. PubMed ID: 31003725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VMAT2-Mediated Neurotransmission from Midbrain Leptin Receptor Neurons in Feeding Regulation.
    Xu Y; Lu Y; Xu P; Mangieri LR; Isingrini E; Xu Y; Giros B; Tong Q
    eNeuro; 2017; 4(3):. PubMed ID: 28560316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine Transporter Localization in Medial Forebrain Bundle Axons Indicates Its Long-Range Transport Primarily by Membrane Diffusion with a Limited Contribution of Vesicular Traffic on Retromer-Positive Compartments.
    Bagalkot TR; Block ER; Bucchin K; Balcita-Pedicino JJ; Calderon M; Sesack SR; Sorkin A
    J Neurosci; 2021 Jan; 41(2):234-250. PubMed ID: 33234607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electron microscopic immunolabeling of transporters and receptors identifies transmitter-specific functional sites envisioned in Cajal's neuron.
    Pickel VM; Garzón M; Mengual E
    Prog Brain Res; 2002; 136():145-55. PubMed ID: 12143378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
    Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
    J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.
    Guillot TS; Miller GW
    Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
    Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.